Novo Nordisk has entered into an agreement with Canadian biotechnology company Aspect Biosystems to develop potentially curative diabetes drugs using cell therapies.[5] Novo will pay $75 million and acquire a worldwide exclusive license to use Aspect's "bioprinting" technology to develop up to four treatments for diabetes and obesity.[1] This technology combines cells and biomaterials to create three-dimensional tissue-like structures that are biologically functional and protected from the immune system.[1] The collaboration initially focuses on therapies that maintain normal blood glucose levels without the need for immunosuppression, which could represent a transformative treatment for patients with type 1 diabetes.[1] The cells will come from the donor, not the patient himself.[1] This partnership builds on an earlier collaboration between the two companies that began in 2023.[2]